More effective, safe medicines are needed to treat ovarian, peritoneal or fallopian tube cancer, particularly for those patients whose cancer has spread and has not responded to current treatments. The research study is testing a potential new treatment, called ZN-c3 (also known as azenosertib; KP-2638), the study drug. This is a clinical research study that will investigate the study drug ZN-c3 to find out if it is safe and whether it will slow or stop the spread of your cancer when taken in combination with chemotherapy such as PLD (pegylated liposomal doxorubicin), Paclitaxel, carboplatin, or gemcitabine.
- Category
-
Trial status
Recruiting
-
Trial phase
Phase 1 Drug TrialEarly stage studies seeking initial evidence of safety, dosage and efficacy in small numbers of patients or healthy volunteers.
- Registry listing
-
ERM Project ID
69078
Trial contact details
-
Contact person
Caitlin Bennett
-
Phone
07 3163 7689
What you need to know
Who can take part
Patients with ovarian, peritoneal or fallopian tube cancer that has spread and has not responded to treatment with other chemotherapy agents including carboplatin or cisplatin.
What is involved for you
You will be asked to take a specific amount of the study drug by mouth with a meal, at approximately the same time each day. This may be for seven days a week, five days a week or four days a week.
You will also be given a Participant diary to record
(1) each dose that you take and the time you take it and
(2) each dose you missed, if any, or if the dose was taken 8 hours or more later than the scheduled time.
You need to bring the diary and the bottle containing the Study Drug (even if it is empty) with you to each clinical visit.
You will also receive one of the following chemotherapy agents:
(2) carboplatin, (3) pegylated liposomal doxorubicin (PLD),(4) paclitaxel, and (5) gemcitabine
